Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Dow
Express Scripts
Baxter
AstraZeneca

Last Updated: June 29, 2022

CLINICAL TRIALS PROFILE FOR AKYNZEO


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Akynzeo

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03008213 ↗ Combination of Netupitant and Palonosetron (Akynzeo┬«) in the Treatment of Refractory CINV Terminated Joseph Ma Phase 2 2017-01-01 Prevention and control of Chemotherapy-Induced Nausea and Vomiting (CINV) are most important in treatment of cancer patients. CINV is one of the most distressing severe side effects of cancer treatment and can have a significant impact on a patient's quality of life. The chemotherapy agents that cause the worst degree of nausea and vomiting are categorized into two groups: moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC). Nausea and vomiting that occurs within the first day of the administration of chemotherapy agents is considered acute CINV, while nausea and vomiting following 24 hours of the administration of chemotherapy agents is considered delayed CINV. Refractory CINV occurs when patients develop CINV during subsequent cycles of chemotherapy when drugs preventing vomiting and nausea (antiemetic prophylaxis) has not been successful in controlling CINV in earlier cycles. The purpose of this study is to assess the efficacy of Akynzeo in the treatment of refractory CINV
NCT03008213 ↗ Combination of Netupitant and Palonosetron (Akynzeo┬«) in the Treatment of Refractory CINV Terminated University of California, San Diego Phase 2 2017-01-01 Prevention and control of Chemotherapy-Induced Nausea and Vomiting (CINV) are most important in treatment of cancer patients. CINV is one of the most distressing severe side effects of cancer treatment and can have a significant impact on a patient's quality of life. The chemotherapy agents that cause the worst degree of nausea and vomiting are categorized into two groups: moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC). Nausea and vomiting that occurs within the first day of the administration of chemotherapy agents is considered acute CINV, while nausea and vomiting following 24 hours of the administration of chemotherapy agents is considered delayed CINV. Refractory CINV occurs when patients develop CINV during subsequent cycles of chemotherapy when drugs preventing vomiting and nausea (antiemetic prophylaxis) has not been successful in controlling CINV in earlier cycles. The purpose of this study is to assess the efficacy of Akynzeo in the treatment of refractory CINV
NCT03040726 ↗ Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer Active, not recruiting Helsinn Healthcare SA Phase 2/Phase 3 2017-05-03 This randomized phase II/III trial studies how well netupitant and palonosetron hydrochloride works in preventing chronic nausea and vomiting in patients with cancer. Netupitant and palonosetron hydrochloride may reduce nausea and vomiting.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Akynzeo

Condition Name

Condition Name for Akynzeo
Intervention Trials
Chemotherapy-induced Nausea and Vomiting 3
Adverse Event 1
Oncology 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Akynzeo
Intervention Trials
Vomiting 6
Nausea 3
Uterine Cervical Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Akynzeo

Trials by Country

Trials by Country for Akynzeo
Location Trials
United States 33
France 1
Greece 1
Denmark 1
Czechia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Akynzeo
Location Trials
Louisiana 2
South Carolina 2
Pennsylvania 2
Ohio 2
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Akynzeo

Clinical Trial Phase

Clinical Trial Phase for Akynzeo
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Akynzeo
Clinical Trial Phase Trials
Recruiting 3
Completed 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Akynzeo

Sponsor Name

Sponsor Name for Akynzeo
Sponsor Trials
Helsinn Healthcare SA 4
National Cancer Institute (NCI) 2
Christina Ruhlmann 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Akynzeo
Sponsor Trials
Other 7
Industry 7
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Moodys
Harvard Business School
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.